Patents by Inventor Anthony A. Estrada

Anthony A. Estrada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-substituted pyrazoles and use as DLK inhibitors
    Patent number: 9550777
    Abstract: The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: January 24, 2017
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Wen Liu, Snahel Patel, Michael Siu
  • SUBSTITUTED SULFONAMIDE COMPOUNDS
    Publication number: 20160264567
    Abstract: The invention is concerned with the compounds of formula I: and salts thereof and other compounds of formulas II-IX as disclosed herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formulas I-IX as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain or asthma.
    Type: Application
    Filed: February 12, 2016
    Publication date: September 15, 2016
    Applicant: Genentech, Inc.
    Inventors: Po-wai YUEN, Anthony ESTRADA, Huifen CHEN, Aleksandr KOLESNIKOV, Elisia VILLEMURE, Vishal VERMA, Lan WANG, Daniel SHORE, Steven DO, Matthew VOLGRAF, Baihua HU, Guosheng WU, Xingyu LIN, Aijun LU
  • SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS
    Publication number: 20160221945
    Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: April 11, 2016
    Publication date: August 4, 2016
    Applicant: GENENTECH, INC.
    Inventors: Huifen CHEN, Yanyan CHU, Steven DO, Anthony ESTRADA, Baihua HU, Aleksandr KOLESNIKOV, Xingyu LIN, Joseph P. LYSSIKATOS, Daniel SHORE, Vishal VERMA, Lan WANG, Guosheng WU, Po-wai YUEN
  • Substituted pyrazoles and uses thereof
    Patent number: 9365583
    Abstract: The present invention provides for compounds of formula 0 and various embodiments thereof, and compositions comprising compounds of formula 0 and various embodiments thereof. In compounds of formula 0, the groups R1A, R1B, R1C, R1D, R2, R3, R4, R5 and R6 have the meaning as described herein. The present invention also provides for methods of using compounds of formula 0 and compositions comprising compounds of formula 0 as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: June 14, 2016
    Assignee: Genentech, Inc.
    Inventors: Michael Siu, Anthony Estrada, Wen Liu, Joseph P. Lyssikatos, Snahel Patel, Guibai Liang, Kevin Chen
  • BIHETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20160052940
    Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
    Type: Application
    Filed: October 29, 2015
    Publication date: February 25, 2016
    Applicant: GENENTECH, INC.
    Inventors: ANTHONY ESTRADA, LITING DONG, KEVIN X. CHEN, PAUL GIBBONS, MALCOLM HUESTIS, TERRY KELLAR, WEN LIU, CHANGYOU MA, JOSEPH LYSSIKATOS, ALAN OLIVERO, SNAHEL PATEL, DANIEL SHORE, MICHAEL SIU
  • Biheteroaryl compounds and uses thereof
    Patent number: 9266862
    Abstract: The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula all have the meaning as defined herein.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: February 23, 2016
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Alan G. Olivero, Snahel Patel, Michael Siu
  • 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS
    Publication number: 20160002228
    Abstract: The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Application
    Filed: July 16, 2015
    Publication date: January 7, 2016
    Applicant: Genentech, Inc.
    Inventors: Anthony ESTRADA, Wen Liu, Snahel Patel, Michael Siu
  • Pyrazole aminopyrimidine derivatives as LRRK2 modulators
    Patent number: 9212173
    Abstract: Pyrazole compounds that are modulators of LRRK2, methods of making the compounds, and methods for using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: December 15, 2015
    Assignee: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Daniel Jon Burdick, Bryan K. Chan, Mark Chambers, Huifen Chen, Anthony Estrada, Zachary Kevin Sweeney
  • Bicyclic pyrazole LRRK2 small molecule inhibitors
    Patent number: 9212186
    Abstract: Compounds of formula I: or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3 and A are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: December 15, 2015
    Assignee: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Bryan K. Chan, Jennafer Dotson, Anthony Estrada, Timothy Heffron, Joseph Lyssikatos, Zachary Sweeney
  • Aminopyrimidine derivatives as LRRK2 modulators
    Patent number: 9145402
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n. X, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: September 29, 2015
    Assignee: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Mark Chambers, Bryan K. Chan, Anthony Estrada, Daniel Shore, Zachary Kevin Sweeney, Huifen Chen
  • Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (PET) imaging for LRRK2
    Patent number: 9139566
    Abstract: A method for positron emission tomography (PET) imaging of LRRK2 in tissue of a subject, the method comprising: administering a compound of formula I, formula II or formula III, or a pharmaceutically acceptable salt thereof to the subject, wherein the compound includes at least one C11 or F18 label thereon; allowing the compound to penetrate into the tissue of the subject; and collecting a PET image of the CNS or brain tissue of the subject.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: September 22, 2015
    Assignee: Genentech, Inc.
    Inventors: Jan Marik, Zachary Kevin Sweeney, Bryan K. Chan, Anthony Estrada
  • SUBSTITUTED SULFONAMIDE SOLUTIONS
    Publication number: 20150197509
    Abstract: The invention is concerned with the compounds of formula (I): and salts thereof, wherein X, Y, Z, R1, R2, R3, R3?, R4, R5 and R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of Formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: March 27, 2015
    Publication date: July 16, 2015
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC.
    Inventors: Christine E. BROTHERTON-PLEISS, Huifen CHEN, Shaoqing CHEN, Zhi CHEN, Shawn David ERICKSON, Anthony ESTRADA, Kyungjin KIM, Hongju LI, Allen John LOVEY, Joseph P. LYSSIKATOS, Yimin QIAN, Sung-Sau SO, Peter Michael WOVKULICH, Lin YI, I
  • SUBSTITUTED PYRAZOLES AND USES THEREOF
    Publication number: 20150175619
    Abstract: The present invention provides for compounds of formula 0 and various embodiments thereof, and compositions comprising compounds of formula 0 and various embodiments thereof. In compounds of formula 0, the groups R1A, R1B, R1C, R1D, R2, R3, R4, R5 and R6 have the meaning as described herein. The present invention also provides for methods of using compounds of formula 0 and compositions comprising compounds of formula 0 as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Application
    Filed: December 19, 2014
    Publication date: June 25, 2015
    Applicant: GENENTECH, INC.
    Inventors: Michael Siu, Anthony Estrada, Wen Liu, Joseph P. Lyssikatos, Snahel Patel, Guibai Liang, Kevin Chen
  • BICYCLIC PYRAZOLE LRRK2 SMALL MOLECULE INHIBITORS
    Publication number: 20150051201
    Abstract: Compounds of formula I: or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3 and A are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Application
    Filed: November 3, 2014
    Publication date: February 19, 2015
    Applicant: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Bryan K. Chan, Jennafer Dotson, Anthony Estrada, Timothy Heffron, Joseph Lyssikatos, Zachary Sweeney
  • PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS
    Publication number: 20150051238
    Abstract: Pyrazole compounds that are modulators of LRRK2, methods of making the compounds, and methods for using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Application
    Filed: November 3, 2014
    Publication date: February 19, 2015
    Applicant: GENENTECH, INC.
    Inventors: Charles Baker-Glenn, Daniel Jon Burdick, Bryan K. Chan, Mark Chambers, Huifen Chen, Anthony Estrada, Zachary Kevin Sweeney
  • BIHETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20140328805
    Abstract: The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula all have the meaning as defined herein.
    Type: Application
    Filed: May 1, 2014
    Publication date: November 6, 2014
    Applicant: GENENTECH, INC.
    Inventors: Anthony Estrada, Alan G. Olivero, Snahel Patel, Michael Siu
  • PYRAZOLOPYRIDINE COMPOUNDS
    Publication number: 20140288043
    Abstract: A first aspect of the invention relates to a compound of formula (1A) or (1B), or a pharmaceutically acceptable salt thereof, Wherein R1 is a group selected from alkyl, monocyclic heterocycloalkyl, bicyclic heterocycloalkyl and cycloalkyl, each of which is optionally substituted, and wherein X1, X2, X3 and X4 are as defined herein. Further aspects relate to pharmaceutical compositions, therapeutic uses and process for preparing compounds of formula (1A) and (1B).
    Type: Application
    Filed: March 19, 2013
    Publication date: September 25, 2014
    Applicant: Genentech, Inc.
    Inventors: Bryan Chan, Anthony Estrada, Daniel Shore, Zachary Sweeney
  • Pyrazole aminopyrimidine derivatives as LRRK2 modulators
    Patent number: 8815882
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: August 26, 2014
    Assignee: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Daniel Jon Burdick, Mark Chambers, Bryan K. Chan, Huifen Chen, Anthony Estrada, Zachary Kevin Sweeney
  • Aminopyrimidine derivatives as LRRK2 modulators
    Patent number: 8809331
    Abstract: Specific Compounds of formula I: or pharmaceutically acceptable salts thereof, wherein m, X, R1, R2, R3, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: August 19, 2014
    Assignee: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Daniel Jon Burdick, Mark Chambers, Bryan K. Chan, Huifen Chen, Anthony Estrada, Janet L. Gunzner-Toste, Daniel Shore, Zachary Kevin Sweeney, Shumei Wang, Guiling Zhao
  • Aminopyrimidine derivatives as LRRK2 modulators
    Patent number: 8802674
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n. X, R1, R2, R3, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Grant
    Filed: December 12, 2012
    Date of Patent: August 12, 2014
    Assignee: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Daniel Jon Burdick, Mark Chambers, Bryan K. Chan, Huifen Chen, Anthony Estrada, Janet Gunzner-Tate, Daniel Shore, Zachary Kevin Sweeney, Shumei Wang, Guiling Zhao